Answer
Relvar Ellipta is contraindicated in patients with hypersensitivity to its active substances or any excipient listed in section 6.1 of its SmPC.
Sources for this answer
- Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensedGlaxoSmithKline UK · emc · SmPC §4.3 Contraindications · Version 19Document updated
Sources checked